Denise Phan, MD
Internal Medicine · van Nuys, CANPI 1477656395
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,778 of the $4,978 with a category attached, or 75.9%. 36 manufacturers reported payments, led by Biohaven Pharmaceuticals, Inc. at 25.4% of the total. Reporting peaked in 2021 at $1,676 and has fallen 52.1% since, to $802 in 2025. Among internal medicine clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 185 payments — averaging $26.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biohaven Pharmaceuticals, Inc.$1K
- AbbVie$1K
- Amgen$333
- Lilly USA, LLC$251
- Pfizer$242
- Novo Nordisk$210
- plus $2K from 30 others
What the payments were for
- Consulting fees$1,20024%
- Food & beverage$3,77876%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biohaven Pharmaceuticals, Inc. | 4 | $1,263 |
| AbbVie(2 entities) | 61 | $1,110 |
| Amgen | 15 | $333 |
| Lilly USA, LLC | 11 | $251 |
| Pfizer | 13 | $242 |
| Novo Nordisk | 11 | $210 |
| Philips North America LLC | 11 | $198 |
| GSK | 5 | $146 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $135 |
| Boehringer Ingelheim | 5 | $121 |
| Phathom Pharmaceuticals, Inc. | 4 | $106 |
| AstraZeneca | 4 | $77 |
| Merck | 3 | $74 |
| Gilead | 3 | $69 |
| Sanofi-aventis U.S. LLC | 3 | $65 |
| Astellas Pharma US Inc | 3 | $56 |
| Vanda Pharmaceuticals Inc. | 2 | $55 |
| Biogen | 2 | $55 |
| Novartis | 2 | $44 |
| Idorsia Pharmaceuticals US Inc | 2 | $32 |
| Topcon Healthcare Solutions, Inc. | 1 | $30 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $30 |
| Nevro Corp. | 1 | $29 |
| Edwards Lifesciences | 1 | $27 |
| Amarin Pharma, Inc. | 1 | $24 |
| Ironwood Pharmaceuticals, Inc | 1 | $24 |
| Dexcom, Inc. | 1 | $23 |
| Linus Health, Inc. | 1 | $23 |
| Eisai Inc. | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Exact Sciences | 1 | $17 |
| Shire North American Group Inc | 1 | $16 |
| Lundbeck LLC | 1 | $16 |
| Apria Healthcare LLC | 1 | $12 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$1,200
How this compares
$4,978 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 56 | $65,504 |
| JardianceEmpagliflozin | 44 | $47,065 |
| TrulicityDulaglutide | 13 | $29,550 |
| MounjaroTirzepatide | 17 | $19,727 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $19,341 |
| JanuviaSitagliptin Phosphate | 15 | $18,771 |
| TradjentaLinagliptin | 27 | $13,470 |
| EliquisApixaban | 11 | $12,234 |
| MyrbetriqMirabegron | 15 | $9,880 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $8,515 |
| Celecoxib | 44 | $5,592 |
| Diclofenac Sodium | 21 | $3,267 |
| Atorvastatin Calcium | 243 | $2,261 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 77 | $2,211 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 50 | $2,198 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $210 | $65,50456 claims |
| Boehringer IngelheimJardiance, Tradjenta | $121 | $60,53571 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $251 | $49,27630 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $146 | $27,85635 claims |
| MerckJanuvia | $74 | $18,77115 claims |
| PfizerEliquis | $242 | $12,23411 claims |
| Astellas Pharma US IncMyrbetriq | $56 | $9,88015 claims |
| AbbVieArmour Thyroid | $1,110 | $57112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.
Other internal medicine in van Nuys
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
- Hatim HusainSan Diego$2M
- Teck LingPalo Alto$1.1M
- Hyong Kimla Jolla$1M
- Rohit Loombala Jolla$965K
- Fred CohenSan Francisco$929K
- Steven EdelmanSan Diego$863K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.